• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Cumberland Pharmaceuticals Inc. (Amendment)

    2/8/22 3:52:52 PM ET
    $CPIX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CPIX alert in real time by email
    SC 13G/A 1 SEC13G_Filing.htm SEC SCHEDULE 13G

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. 6 )*

                

    Cumberland Pharmaceuticals Inc


    (Name of Issuer)

    Common Stock


    (Title of Class of Securities)

    230770109


    (CUSIP Number)

    December 31, 2021


    (Date of Event Which Requires Filing of this Statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    [X] Rule 13d-1(b)
    [ ] Rule 13d-1(c)
    [ ] Rule 13d-1(d)

    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 (the "Act") or otherwise subject to the liabilities of that section of the Act, but shall be subject to all other provisions of the Act (however, see the Notes.)


    CUSIP No. 230770109

    1. NAMES OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

    Dimensional Fund Advisors LP
    30-0447847
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

    (a) [ ]
    (b) [X]
    3. SEC USE ONLY
    4. CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware Limited Partnership

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

    5. SOLE VOTING POWER 636,894 ** see Note 1 **
    6. SHARED VOTING POWER 0
    7. SOLE DISPOSITIVE POWER 652,561 ** see Note 1 **
    8. SHARED DISPOSITIVE POWER 0
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    652,561 ** see Note 1 **
    10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    [ ]
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    4.4%
    12. TYPE OF REPORTING PERSON

    IA

    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    


    Item 1.
    (a) Name of Issuer
    Cumberland Pharmaceuticals Inc
    (b) Address of Issuer's Principal Executive Offices
    2525 West End Avenue, Suite 950, Nashville, TN 37203
    Item 2.
    (a) Name of Person Filing
    Dimensional Fund Advisors LP
    (b) Address of Principal Business Office or, if None, Residence
    6300 Bee Cave Road, Building One, Austin, TX 78746
    (c) Citizenship
    Delaware Limited Partnership
    (d) Title of Class of Securities
    Common Stock
    (e) CUSIP Number
    230770109
    Item 3. If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:
    (a) [ ] Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o).
    (b) [ ] Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c).
    (c) [ ] Insurance Company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c).
    (d) [ ] Investment Company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
    (e) [X] An investment adviser in accordance with Rule 240.13d-1(b)(1)(ii)(E);
    (f) [ ] An employee benefit plan or endowment fund in accordance with Rule 240.13d-1(b)(1)(ii)(F);
    (g) [ ] A parent holding company or control person in accordance with Rule 240.13d-1(b)(1)(ii)(G);
    (h) [ ] A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i) [ ] A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j) [ ] Group, in accordance with Rule 240.13d-1(b)(1)(ii)(J).
    Item 4. Ownership.
    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
    (a) Amount Beneficially Owned:
    652,561 ** see Note 1 **
    (b) Percent of Class:
    4.4%
    (c) Number of shares as to which such person has:
    (i) sole power to vote or to direct the vote 636,894 ** see Note 1 **
    (ii) shared power to vote or to direct the vote 0
    (iii) sole power to dispose or to direct the disposition of 652,561 ** see Note 1 **
    (iv) shared power to dispose or to direct the disposition of 0
    ** Note 1 ** Dimensional Fund Advisors LP, an investment adviser registered under Section 203 of the Investment Advisors Act of 1940, furnishes investment advice to four investment companies registered under the Investment Company Act of 1940, and serves as investment manager or sub-adviser to certain other commingled funds, group trusts and separate accounts (such investment companies, trusts and accounts, collectively referred to as the "Funds"). In certain cases, subsidiaries of Dimensional Fund Advisors LP may act as an adviser or sub-adviser to certain Funds. In its role as investment advisor, sub-adviser and/or manager, Dimensional Fund Advisors LP or its subsidiaries (collectively, "Dimensional") may possess voting and/or investment power over the securities of the Issuer that are owned by the Funds, and may be deemed to be the beneficial owner of the shares of the Issuer held by the Funds. However, all securities reported in this schedule are owned by the Funds. Dimensional disclaims beneficial ownership of such securities. In addition, the filing of this Schedule 13G shall not be construed as an admission that the reporting person or any of its affiliates is the beneficial owner of any securities covered by this Schedule 13G for any other purposes than Section 13(d) of the Securities Exchange Act of 1934.
    Item 5. Ownership of Five Percent or Less of Class.
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: [ X ]
    Item 6. Ownership of More than Five Percent on Behalf of Another Person.
    The Funds described in Note 1 above have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of the securities held in their respective accounts. To the knowledge of Dimensional, the interest of any one such Fund does not exceed 5% of the class of securities. Dimensional Fund Advisors LP disclaims beneficial ownership of all such securities.
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.
    Not Applicable
    Item 8. Identification and Classification of Members of the Group.

    Not Applicable. This schedule is not being filed pursuant to Rule 13d-1(b)(1)(ii)(J) or Rule 13d-1(d).
    Item 9. Notice of Dissolution of Group.

    Not Applicable
    Item 10. Certification.

    By signing below, I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dimensional Fund Advisors LP
    By: Dimensional Holdings Inc., General Partner
    By: /s/ Selwyn Notelovitz
    Date: February 14, 2022
    Name: Selwyn Notelovitz
    Title: Global Chief Compliance Officer

    Get the next $CPIX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CPIX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $CPIX
    SEC Filings

    View All

    SEC Form DEFM14A filed by Cumberland Pharmaceuticals Inc.

    DEFM14A - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Filer)

    5/26/26 6:00:54 AM ET
    $CPIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form PREM14A filed by Cumberland Pharmaceuticals Inc.

    PREM14A - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Filer)

    5/15/26 4:27:35 PM ET
    $CPIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Cumberland Pharmaceuticals Inc.

    10-Q - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Filer)

    5/8/26 5:02:07 PM ET
    $CPIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CPIX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Cumberland Pharmaceuticals and Vanderbilt Health Announce Potential New Therapy to Prevent Cancer Metastasis

    Positive Results from Phase 2a Clinical TrialStudy met its primary endpoint demonstrating safety and tolerability of ifetroban in patients with high-risk solid tumorsTrial revealed promising efficacy signals with fewer deaths due to metastasis in the ifetroban arm, than in the placebo arm (p=0.037)Results support development of ifetroban as a candidate for metastasis preventionNASHVILLE, Tenn., June 2, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company focused on developing new products for rare diseases, and Vanderbilt Health today announce data from a Phase 2a clinical trial of ifetroban to prevent metastasis in high-risk solid tumors. Th

    6/2/26 9:05:00 AM ET
    $CPIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    RedHill Biopharma Advancing Opaganib Options for Novel Dual Host Directed and Direct Acting Antiviral Approach for Ebola Outbreak Biodefense Platforms

    Amid the rapidly evolving Ebola virus disease (EVD) outbreak involving the rare Bundibugyo ebolavirus sub-type, for which there are no approved medications or vaccines, RedHill Biopharma is actively discussing potential collaborations for clinical advancement of opaganib1, including the World Health Organization's (WHO) SOLIDARITY CORE clinical trial platformOpaganib EVD rationale (analogous to EVD treatment pathway):Phase 3 clinical antiviral activity (severe COVID-19) showing2:70.2% mortality reduction with opaganib given as add-on to best available standard of care (remdesivir + corticosteroids): 6.98% (n=3/43) opaganib + SoC vs. 23.4% (n=11/47) placebo + SoC (p=0.034)) Improved median ti

    6/2/26 8:00:00 AM ET
    $CPIX
    $RDHL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CUMBERLAND PHARMACEUTICALS ANNOUNCES LAUNCH OF VIBATIV® IN CHINA

    Commercialization in China through partnership with SciClone PharmaceuticalsExpands access to potentially life-saving antibiotic in the world's second-largest pharmaceutical marketNASHVILLE, Tenn., May 28, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), an innovation focused biopharmaceutical company, today announced the launch of its Vibativ® (telavancin) injection in China, following regulatory approval and a strategic partnership with SciClone Pharmaceuticals (Holdings) Limited. The launch follows a previously announced agreement granting SciClone exclusive rights to register, promote and distribute telavancin, injection across China. The product's approval by China's

    5/28/26 9:05:00 AM ET
    $CPIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CPIX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Brown Martin S Jr

    4 - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Issuer)

    3/20/26 5:24:05 PM ET
    $CPIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Galante Joseph C

    4 - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Issuer)

    3/20/26 5:23:43 PM ET
    $CPIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Jones James

    4 - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Issuer)

    3/20/26 5:22:41 PM ET
    $CPIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CPIX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Young Caroline bought $398 worth of shares (121 units at $3.29), increasing direct ownership by 0.37% to 32,942 units (SEC Form 4)

    4 - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Issuer)

    9/12/25 8:36:28 AM ET
    $CPIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Jones James bought $862 worth of shares (262 units at $3.29), increasing direct ownership by 0.60% to 43,938 units (SEC Form 4)

    4 - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Issuer)

    9/12/25 8:35:26 AM ET
    $CPIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chairman and CEO Kazimi A J bought $862 worth of shares (262 units at $3.29), increasing direct ownership by 0.00% to 5,700,030 units (SEC Form 4)

    4 - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Issuer)

    9/12/25 8:34:18 AM ET
    $CPIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CPIX
    Financials

    Live finance-specific insights

    View All

    CUMBERLAND PHARMACEUTICALS TO ANNOUNCE Q1 2026 FINANCIAL RESULTS & COMPANY UPDATE

    NASHVILLE, Tenn., April 28, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company, announced today that it will release its first quarter 2026 financial results and provide a company update after the market closes on Tuesday, May 5, 2026. A conference call will be held on May 5 at 4:30 p.m. Eastern Time to discuss the results and update.The link to register is https://register-conf.media-server.com/register/BI31a40566a8cb4846873ec8b25642be3a.Once registered, participants can dial in from their phone using a dial-in and PIN number that will be provided to them. Alternatively, they can choose a "Call Me" option to have the system automatically c

    4/28/26 4:05:00 PM ET
    $CPIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CUMBERLAND PHARMACEUTICALS ANNOUNCES EXPANDED INDICATION FOR CALDOLOR® (IBUPROFEN) INJECTION AND LAUNCH OF NEW BRAND WEBSITE

    A Safe and Effective Non-Opioid Pain Management SolutionNASHVILLE, Tenn., April 16, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company, today announced it has received approval from the U.S. Food and Drug Administration (FDA) for an expanded indication for its Caldolor® (ibuprofen) Injection product. The indication now includes the management of postoperative pain, and the approval coincides with the launch of a newly designed website for healthcare professionals highlighting this advancement and the evolving role of non-opioid pain management.   With this update, Caldolor is indicated for use in adult and pediatric patients ages 3 months a

    4/16/26 9:05:00 AM ET
    $CPIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cumberland Pharmaceuticals Launches New Sancuso® Website Featuring Educational Resources for Chemotherapy-Induced Nausea and Vomiting

    Sancuso – the Difference Between Life and LivingNASHVILLE, Tenn., March 17, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company today announced the launch of its new Sancuso® (granisetron transdermal system) website. The website is designed to provide health care professionals and patients with enhanced access to educational resources, clinical information and expert insights related to the prevention of chemotherapy-induced nausea and vomiting (CINV). The website also features the brand's key message: "Sancuso – the Difference between Life and Living."

    3/17/26 9:05:00 AM ET
    $CPIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CPIX
    Leadership Updates

    Live Leadership Updates

    View All

    Sitryx appoints Adam Mostafa as Chief Financial Officer

    Sitryx appoints Adam Mostafa as Chief Financial Officer Adam joins Sitryx with deep expertise in biotechnology capital markets, M&A and business development and strategic leadership Oxford, UK and Boston, MA – 8 September 2025 – Sitryx Therapeutics ("the Company"), a clinical-stage biopharmaceutical company developing novel oral therapies to restore immune balance in autoimmune and inflammatory disease, today announces the appointment of Adam Mostafa as Chief Financial Officer (CFO), effective today. With over 25 years of experience, Adam is a seasoned biotech executive and financial leader. He joins Sitryx with a distinguished background spanning across biotech and healthcare financial

    9/8/25 7:00:00 AM ET
    $ABP
    $CPIX
    $XFOR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    CUMBERLAND PHARMACEUTICALS APPOINTS MARTIN BROWN JR. TO ITS BOARD OF DIRECTORS

    NASHVILLE, Tenn., July 19, 2022 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company, announced today that Martin Brown Jr. has joined the company's Board of Directors. Brown previously served for 10 years on the Board of directors of Brown-Forman Corporation, a large American wine and spirits company listed on the New York Stock Exchange. The brands in Brown-Forman's portfolio include Jack Daniel's and Woodford Reserve whiskeys, Benriach scotch, Herradura tequila and Finlandia vodka.  Brown is an attorney at Adams and Reese LLP, a

    7/19/22 9:25:00 AM ET
    $CPIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CPIX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Cumberland Pharmaceuticals Inc.

    SC 13G - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Subject)

    2/9/24 5:27:23 PM ET
    $CPIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Cumberland Pharmaceuticals Inc.

    SC 13G - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Subject)

    2/10/23 5:01:42 PM ET
    $CPIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Cumberland Pharmaceuticals Inc.

    SC 13G - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Subject)

    2/14/22 5:17:27 PM ET
    $CPIX
    Biotechnology: Pharmaceutical Preparations
    Health Care